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ABSTRACT
Introduction: Postherpetic neuralgia (PHN), a
type of peripheral neuropathic pain (pNeP), is
the most common complication of herpes
zoster. The objective of this analysis was to
determine the cost-effectiveness of pregabalin
compared with gabapentin in pNeP and PHN in
China.
Methods: We developed a China-localized
12-week simulation model to determine the
cost-effectiveness of pregabalin compared to
gabapentin in 1000 patients with pNeP and
PHN. We utilized a questionnaire of Chinese
key opinion leaders to estimate the
pre-treatment distribution of pain scores for
pNeP and PHN. Treatment outcomes for
pregabalin and gabapentin were acquired from
the published literature.
Results: Treatment with pregabalin lead to
12-week decreases in pain scores of 0.6 (pNeP)
and 0.7 (PHN) when compared to patients
receiving gabapentin, at an incremental cost
per additional day of mild/no pain of $45. The
difference in mean days of no or mild pain,
moderate pain, and severe pain was 8.8, -5.7,
and -3.1, when comparing pregabalin and
gabapentin, respectively. Pregabalin had more
mean days with a [30% (7.71 days), 40%
(8.97 days), and 50% reduction (9.97 days) in
pain when compared with gabapentin. In the
pNeP scenario, pregabalin was associated with a
lower average pain score compared with
gabapentin (3.91 vs. 4.55). The difference in
mean days of no or mild pain, moderate pain,
and severe pain was 9.39, -5.56, and -3.82,
when comparing pregabalin and gabapentin,
respectively. Pregabalin had more mean days
with a[30% (8.77 days), 40% (9.81 days), and
50% reduction (10.55 days) in pain when
compared with gabapentin.
Conclusion: Pregabalin is an effective
treatment for PHN and even for pNeP
extensively, but at increased cost. It leads to
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INTRODUCTION
Peripheral neuropathic pain (pNeP) is a general
pain disorder caused by a lesion or disease of the
peripheral somatosensory nervous system and
occurs frequently with diabetes or following
herpes zoster reactivation. The symptoms of
pNeP may include numbness, tingling,
weakness, and burning, and may lead to more
severe events such as higher blood pressure,
vomiting, and diarrhea. Postherpetic neuralgia
(PHN) is a persistent, debilitating type of pNeP
lasting months to years and is themost common
complication of herpes zoster. PHN/pNeP
severity is a primary predictor of negative health
impact, with the more severe patients reporting
low levels of health-related quality of life [1].
China’s rapidly aging population portends a
coming transition from acute illness as its
primary health challenge to chronic diseases
[2], which require long-term, tailored solutions
based on individual patient characteristics. It is
generally believed that the prevalence of pNeP
and PNP will continue to increase globally due
to the aging of the population and higher
survival rates from conditions that are
associated with pNeP (such as cancer, HIV
infection, and diabetes) [3].
Vera-Llonch et al. [4] developed a 12-week
stochastic simulation model to examine the
treatment of pNeP; this work was adapted by
Tarride et al. [5] into a cost-effectiveness model
comparing pregabalin versus gabapentin in the
management of diabetic peripheral neuropathy
(DPN) and PHN in a Canadian setting.
Compared to gabapentin, pregabalin was
projected to result in 6 and 9 additional days
with no or mild pain, and 0.005 and 0.009
quality-adjusted life years (QALYs), for patients
with DPN and PHN, respectively. The adapted
Canadian model utilized a global perspective to
facilitate future adaptations to the healthcare
perspectives of additional countries.
Although the cost-effectiveness of pregabalin
has previously been assessed in the UK [6] and
Spain [7], no comparable studies to date have
assessed the costs and health impacts for China.
The objective of this study was to assess the
cost-effectiveness of pregabalin compared with
gabapentin in pNeP and PHN from a Chinese
healthcare perspective using a China-localized
adaptation of the Tarride et al. [5] model.
METHODS
Approach
We adapted the Tarride et al. [5] decision model
to evaluate the short-term incremental
cost-effectiveness of pregabalin versus
gabapentin in China [8]. The analysis was
conducted from a Chinese health system
perspective using a 12-week time horizon
based on duration of follow-up in the
pregabalin clinical trials [9, 10]. Treatment
strategies included pregabalin and generic
gabapentin, with the goal of treatment being
to reduce daily pain severity. China-specific
alterations to the Tarride et al. [5] model
included resource utilization rates, resource
costs, drug costs, treatment pathways, and
mortality. Due to the short 12-week time
horizon, we excluded costs and outcomes
discounting, as well as consideration of QALYs
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and thus incremental cost-effectiveness ratios
(ICERs). The decision to exclude the ICER also
stems from a World Health Organization
suggestion that gross domestic product-based
willingness-to-pay per QALY thresholds in
developing countries such as China are
imperfect and should consider the relevant
context of other available public health
options, healthcare budgets, and the role of
decision makers [11]. All costs are presented in
2015 US dollars and were converted using an
exchange rate of 6.07 RMB = 1 USD. The model
was programmed in Microsoft Excel (Microsoft
Corporation, Redmond, WA, USA).
Model Structure
We utilized a three-state (severe, moderate, or
no pain) Markov model (Fig. 1) to represent
variable pain scores and associated health state
utilities and costs, with a cycle length of 1 day.
For any given patient, pain was assumed to vary
daily, thus patients could move from one state
to another with each cycle. Patient resource use
was calculated using a decision analytic model
(Fig. 2) based on the probability of a general
practitioner visit followed by subsequent
probabilities for additional resources.
Model Outcomes
The primary model outcomes were: (1)
post-treatment pain score, (2) total number of
days with no or mild pain, (3) drug costs, and (4)
total medical-care services costs. Secondary
outcomes included: (1) mean number of days
with30%,40%and50%reduction inpain scores,
(2)mean number of daysC2 or 3 point reduction
in pain, and (3) cost per additional daywithno or
mild pain. Pain was measured on an 11-point
numeric pain rating scale (0 = no pain,
10 = severe pain). Severe pain was classified as
pain severity from 7 to 10, moderate pain from 4
to 6, and mild pain from 1 to 3.
Population
We modeled the patient population based on
clinical trial data of patients with pNeP which
includes patients with both PHN and DPN, and/
or PHN. Patients had moderate to severe pain at
treatment initiation, and received an average
daily dose of 372 mg/day for pregabalin and
2400 mg/day for gabapentin, although dosage
was modifiable through scenario analysis.
Patient pain was assumed to be intractable to
therapies for underlying conditions.
Fig. 1 Markov model structure. The Markov model
structure consists of three health states: no pain or mild
pain; moderate pain; and severe pain. Pain scores determine
these health states, which each have individual utilities and
probabilities of resource utilization and costs attached
Pain Ther (2016) 5:81–91 83
Model Parameters
The model includes data from a variety of
sources including physician surveys,
randomized clinical trials, and published
literature. We identified China-localized model
parameters through literature review and a
questionnaire of eleven key opinion leaders
(Chinese specialists and general practitioners),
who provided estimates of initial pain scores
specific to the Chinese pNeP and PHN patient
populations (Table 1). Efficacy estimates
(Table 2) were obtained from published
literature and were modeled for each week as
the percentage reduction in baseline pain score
[1]: pregabalin efficacy in pNeP was taken from
Protocol 1008-155 [9] and has been used
previously [4]; gabapentin efficacy in pNeP was
taken from the pooled analysis of two
randomized clinical trials [12, 13].
The probability of a doctor visit was unique
to a patient’s pain score on any given week and
reflected results from the key opinion leader
survey (Table 3). Patients who visited a doctor
utilized healthcare resources according to
results from the survey (Table 4). Drug costs
included the cost of pregabalin and gabapentin
(Table 5). The cost of pregabalin was based on
the average trial dose of 372 mg per day.
Assumptions
We assumed clinical management was similar
for PHN and DPN patients. Adverse events were
not included in the model because no clinically
relevant differences exist between pregabalin
and gabapentin within the 12-week time
horizon. Rates of therapy discontinuation due
to adverse events or lack of efficacy were also
assumed to be the same between therapies. We
assumed primary care providers clinically
managed all patients, and that the likelihood
Fig. 2 Resource utilization decision tree. A probability of a doctor’s visit is assigned to patients in each health state, patients
then have probabilities of consuming additional resources and costs if they visit a doctor. GP general practitioner
Table 1 Pre-treatment pain scores
Score pNeP (%) PHN (%)
4.0 to\5.0 18.00 8.89
5.0 to\6.0 18.18 15.33
6.0 to\7.0 19.27 19.11
7.0 to\8.0 19.55 18.89
8.0 to\9.0 16.36 23.33
9.0 to 10.0 8.64 14.44
The pre-treatment pain score distributions were sourced
from the physician survey. The distribution shows the
percentage of patients within each pain score threshold for
both the pNeP and PHN populations
pNeP peripheral neuropathic pain, PHN postherpetic
neuralgia
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that patients will visit their primary care
provider in a given week was a function of
average level of pain. The efficacy of additional
healthcare services is unknown, particularly if
used in conjunction with pregabalin or other
pharmacotherapy, thus we did not assign
health benefits to them.
Analysis
The 12-week model was designed to estimate
the impact of pharmacotherapy on daily pain
experience using Bayesian simulation
techniques to estimate patients’ daily pain
experience (measured on 0–10 scale) over
time. The expected mean reductions (vs.
baseline) in average daily pain scores for
therapies of interest were applied to each
patient’s daily pain scores on a weekly basis
to generate expected daily pain scores with
treatment. We calculated various summary
measures of patient outcomes based on
expected daily pain scores for each treatment
of interest. Summary measures of the outcomes
were combined with utilization of healthcare
services, costs of care, and health state utilities
to calculate the cost-effectiveness of pregabalin
versus gabapentin. We explored parameter
uncertainty using a probabilistic sensitivity
analysis of 1000 simulations of 1000 patients
each, and calculated the mean and 95%
credible interval for each model outcome.
Table 2 Weekly percentage reduction in pain score
Week Peripheral neuropathic pain Postherpetic neuralgia
Pregabalin (%) Gabapentin 2400 mg (%) Pregabalin (%) Gabapentin 2400 mg (%)
1 13.7 17.2 14.7 17.3
2 23.2 24.2 23.3 24.9
3 29.9 27.5 29.5 29.2
4 39.1 29.9 40.3 31.2
5 44.4 31.5 46.6 32.7
6 44.2 32.7 43.9 33.7
7 45.0 33.6 43.9 34.5
8 46.3 34.2 45.1 35.0
9 49.8 34.6 49.1 35.4
10 51.1 34.9 50.6 35.7
11 53.3 35.2 57.5 35.9
12 54.1 35.3 58.2 36.0
The weekly percentage reductions in pain score are shown for each week of the model for both medications and
populations. These percentages contribute to the transition probabilities within the Markov model
Table 3 Probability of a doctor visit according to
physician survey
Health state Probability (%)
Mild pain (0.0 to\4.0) 8.89
Moderate pain (4.0 to\7.0) 15.33
Severe pain (7.0 to\10.0) 19.11
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Compliance with Ethics Guidelines
This analysis in this article is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
RESULTS
The results of the pNeP and PHN analyses are
summarized in Table 6. The mean
pre-treatment pain scores were 6.7 for patients
with pNeP and 7.2 for patients with PHN. At
12 weeks post-treatment initiation, the mean
pain scores for the pNeP population were 3.9
and 4.5 for those treated with pregabalin and
gabapentin, respectively. In the PHN
population, 12-week mean pain scores were
4.2 and 4.9 for patients treated with
pregabalin and gabapentin, respectively.
Treatment with pregabalin resulted in an
additional decrease of 0.6 and 0.7 when
compared to patients receiving gabapentin in
the pNeP and PHN populations, respectively.
In the pNeP population, pregabalin resulted
in an increase of 9.5 days of no or mild pain, a
decrease of -6.1 days of moderate pain, and a
decrease of -3.5 days of severe pain compared
to gabapentin. Pregabalin had more mean days
with a C30% (8.3 days), 40% (9.7 days), and
50% reduction (10.8 days) in pain when
compared with gabapentin. In the PHN
population, pregabalin resulted in an increase
of 9.6 days of no or mild pain, a decrease of
Table 4 Resource utilization
Resource Probability Cost per unit Number of units
Doctor visit See Table 3 $52.72 1
Computed tomography (CT Scan) 0.231 $55.19 1
Magnetic resonance imaging (MRI) 0.23222 $131.14 1
Nerve conduction studies 0.415 $41.52 1
Quantitative sensory testing 0.485 $21.97 1
Doppler sonograph 0.121111 $27.18 1
Electromyography (EMG) 0.44090 $47.12 1
Transcutaneous electronic nerve stimulation 0.16857 $27.80 1
Implantation of spinal stimulator 0.018 $20,560 1
Physical therapy 0.538888 $27.41 2
Nerve block 0.526666 $135.42 1.33333
Resource utilization probabilities and costs were sourced from the physician survey. The probability of a doctor’s visit was
based on the patient’s health state (Table 3). The probabilities of the other resources being utilized were assigned to patients
who visited the doctor








$8.32 Pﬁzer, data on ﬁle
Gabapentin
(2400 mg/day)
$2.96 Pﬁzer, data on ﬁle
a The average dose of pregabalin was 372 mg per day
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-5.5 days of moderate pain, and a decrease of
-4.1 days of severe pain compared to
gabapentin. Pregabalin had more mean days
with a C30% (7.8 days), 40% (9.2 days), and
50% reduction (10.2 days) in pain when
compared with gabapentin.
The cost per additional day of mild/no pain
was calculated for both patient populations
(Tables 7, 8). The total costs were higher in
both populations in patients treated with
pregabalin. In pNeP patient pregabalin
resulted in an additional $427 in total costs
when compared with gabapentin. For the PHN
population, total costs were an additional $429
for pregabalin treatment compared to
gabapentin.
Table 6 Model outcomes
Outcomes pNeP PHN
Pregabalin Gabapentin Difference Pregabalin Gabapentin Difference
Pre-treatment
pain score
6.7 (0) 6.7 (0) 0 (0) 7.2 (0) 7.2 (0) 0 (0)
Post-treatment
pain score
3.9 (0.02) 4.5 (0.02) -0.6 (0.03) 4.2 (0.02) 4.9 (0.02) -0.7 (0.03)
Days no/mild
pain
40.1 (0.3) 30.5 (0.3) 9.5 (0.42) 35.5 (0.32) 25.9 (0.30) 9.6 (0.44)
Days moderate
pain
30.2 (0.3) 36.3 (0.32) -6.1 (0.44) 31.3 (0.32) 36.8 (0.32) -5.5 (0.46)
Days severe
pain
13.7 (0.23) 17.2 (0.25) -3.5 (0.34) 17.2 (0.25) 21.3 (0.27) -4.1 (0.37)
Days C30%
reduction
50.9 (0.34) 42.6 (0.36) 8.3 (0.5) 50.6 (0.33) 42.8 (0.36) 7.8 (0.48)
Days C40%
reduction
44.4 (0.34) 34.7 (0.35) 9.7 (0.47) 43.3 (0.34) 34.1 (0.35) 9.2 (0.47)
Days C50%
reduction
37.5 (0.34) 26.7 (0.33) 10.8 (0.46) 36.3 (0.34) 26.1 (0.33) 10.2 (0.46)
Days C2-point
reduction
56.2 (0.32) 49.3 (0.36) 6.9 (0.49) 57.4 (0.33) 51.2 (0.35) 6.2 (0.48)
Days C3-point
reduction
42.2 (0.34) 32.8 (0.33) 9.4 (0.47) 44.4 (0.33) 35.8 (0.34) 8.6 (0.46)
Drug costs $685 ($0) $243 ($0) $441 ($0) $685 ($0) $243 ($0) $441 ($0)
Non-drug costs $731 ($88.79) $745 ($89.16) -$15 ($121.86) $742 ($89.75) $755 ($88.27) -$13 ($120.98)
Total costs $1415 ($88.81) $989 ($89.36) $427 ($122.27) $1427 ($89.74) $998 ($88.07) $429 ($120.97)
The model outcomes for both the pNeP and PHN patient populations are presented as the mean (standard deviation) result
of each simulation
pNeP peripheral neuropathic pain, PHN postherpetic neuralgia
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In both populations, pregabalin treatment
resulted in more additional days on mild/no
pain and higher costs. In the pNeP patient
population, treatment with pregabalin resulted
in 9.5 additional days of mild/no pain at an
additional cost of $427, resulting in an
incremental cost per additional day of mild/no
pain of $44.69. In the PHN patient population,
treatment with pregabalin had 9.6 additional
days of mild/no pain at $429 additional cost,
resulting in an incremental cost per additional
day of mild/no pain of $44.74.
DISCUSSION
We developed a China-localized decision
model to determine the cost-effectiveness of
pregabalin compared with gabapentin in pNeP
and PHN patient populations. We found that
treatment with pregabalin leads to decreases in
pain scores of 0.6 (pNeP) and 0.7 (PHN) when
compared to patients receiving gabapentin, at
an incremental cost per additional day of mild/
no pain of $45. Treatment with pregabalin
provided 9.5 and 9.6 additional days of mild/
no pain and in the pNeP and PHN patient
populations, respectively, suggesting that
substantial improvements in patient quality
of life are possible for these patient
populations. Our results were robust to
variation in model parameters in probabilistic
sensitivity analysis.
pNeP represents a broad class of
neuropathies associated with high pain levels,
low utility scores, poor sleep, depression, and
anxiety, though not on survival. Adding to this
complexity, approximately half of pNeP
patients are satisfied overall with their current
pain medication [14]. Therefore, it is imperative
to make more treatment options available to
patients, so that a multifaceted approach to
treatment is possible for each unique expression
of patient pain. Given the increasing societal
burden of these chronic diseases in China,
government payers may need to increase
coverage for effective treatments such as
pregabalin. This will provide the necessary
access to the medications that can improve
Table 7 Cost per additional day of mild/no pain
Variable Pregabalin Gabapentin Difference
Days of mild/no pain 40.06 (39.46–40.67) 30.52 (29.90–31.11) 9.53 (8.74–10.34)
Total costs $1415 ($1253–$1599) $989 ($821–$1169) $427 ($199–$678)
Cost per day of mild/no pain $44.74 ($20.96–$71.91)
The results of the peripheral neuropathic pain population analysis are shown. The results are presented as the mean (95%
conﬁdence interval) of the simulations
Table 8 Cost per additional day of mild/no pain
Variable Pregabalin Gabapentin Difference
Days of mild/no pain 35.50 (34.86–36.12) 25.91 (25.35–26.50) 9.59 (8.71–10.44)
Total costs $1427 ($1257–$1612) $998 ($830–$1180) $429 ($203–$692)
Cost per day of mild/no pain $44.69 ($20.92–$71.91)
The results of the postherpetic neuralgia population analysis are shown. The results are presented as the mean (95%
conﬁdence interval) of the simulations
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quality of life and thus, potentially, increase
productivity and output for the economy.
Randomized, placebo-controlled clinical
trials have shown that pregabalin provides
statistically and clinically significant
improvements in pNeP associated with DPN
and PHN [15–19]. The results of our modeling
study are similar to the previous Canadian
setting adaptation (6 and 9 additional days
with no or mild pain for patients with DPN and
PHN, respectively). However, our model
differed from this previous model by excluding
consideration of QALYs because of the
perceived limitations imposed by the short
time horizon of our model. Furthermore, there
has been a shift toward alternative metrics of
pNeP health outcomes because clinicians are
increasingly appreciating outcomes reduction,
such as clinical cure, days with no pain, and
glycated hemoglobin (HbA1c), because of the
ease of measurement and explanation to
patients [20–22]. Lastly, we recognize that the
QALY may not be the measure of choice for the
Chinese health system, and that pain-free days
are more likely to have buy-in from patients and
clinicians alike.
Our model had several other limitations
worth noting. First, we limited the time
horizon to a 12-week period of follow-up
based on available trial data; pain in patients
with peripheral neuropathies may last for much
longer. Second, we did not consider adverse
events in our model because we assumed
adverse event rates and rates of
discontinuation due to adverse events were
similar for both treatment populations,
primarily because of the short time horizon
chosen for the model. In a longer-term model,
these rates would be expected to exhibit
differences. Third, patients who were referred
to specialists were assumed to have received
additional healthcare services, which may have
had an impact on the costs associated with any
given treatment strategy.
Fourth, the model was primarily based on
randomized clinical trial data of predominantly
white patients that may not represent the real
treatment effects, heterogeneity, and drug
adherence in a Chinese setting. If
China-specific clinical trial data were available
we would have used it instead; nonetheless,
clinical trial evidence is the gold standard of
evidence for decision modeling studies, and
while the populations studied may be highly
specific, the data produced in the trials is of
greater accuracy and credibility than educated
guesses. The incorporation of data from other
studies may provide different estimates than
those we have calculated; however, we believe
the parameters selected for this model represent
the best available evidence. Lastly, we chose to
omit the standard ICER measure of
cost-effectiveness because the model’s time
horizon is brief at only 12 weeks, and because
pNeP/PHN is not a fatal condition, thus any
assessment of survival and quality-adjusted
survival is inherently limited. In lieu of an
ICER, the cost per day of no/mild pain is a plain
language representation of value that may be of
greater use in the Chinese healthcare setting.
CONCLUSIONS
Pregabalin appears to be an effective treatment
for PHN and pNeP at an incremental cost per
additional day of mild/no pain of $45, leading
to improved outcomes including lower pain
scores and an increase in days with no or mild
pain, in a Chinese setting. Adding pregabalin to
the treatment paradigm for pNeP/PHN would
provide physicians with an additional weapon
to treat patients with pNeP/PHN that provides a
great value.
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